Last reviewed · How we verify
dabigatran etexilate mesylate capsules 150mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
dabigatran etexilate mesylate capsules 150mg (dabigatran etexilate mesylate capsules 150mg) — The Affiliated Hospital Of Guizhou Medical University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| dabigatran etexilate mesylate capsules 150mg TARGET | dabigatran etexilate mesylate capsules 150mg | The Affiliated Hospital Of Guizhou Medical University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- dabigatran etexilate mesylate capsules 150mg CI watch — RSS
- dabigatran etexilate mesylate capsules 150mg CI watch — Atom
- dabigatran etexilate mesylate capsules 150mg CI watch — JSON
- dabigatran etexilate mesylate capsules 150mg alone — RSS
Cite this brief
Drug Landscape (2026). dabigatran etexilate mesylate capsules 150mg — Competitive Intelligence Brief. https://druglandscape.com/ci/dabigatran-etexilate-mesylate-capsules-150mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab